BetaGlue Therapeutics
Phase 1BetaGlue Therapeutics develops innovative targeted cancer therapy solutions using its proprietary YntraDose technology for nuclear medicine.
Founded
2015
Focus
Radiopharmaceuticals
About
BetaGlue Therapeutics develops innovative targeted cancer therapy solutions using its proprietary YntraDose technology for nuclear medicine.
Funding History
1Total raised: $3.5M
Seed$3.5MPanakes PartnersJan 15, 2023
Company Info
TypePrivate
Founded2015
LocationMilan, Italy
StagePhase 1
Contact
SIMILAR COMPANIES
AAVantgarde Bio
Pre-clinical · Milan
AB ANALITICA
Pre-clinical · Padua
Adienne Pharma and Biotech
Pre-clinical · Milan
Advaxia Biologics
Pre-clinical · Milan
Alia Therapeutics
Pre-clinical · Trento
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile